| Kevin Liebrum, CRNA | |
|
1515 N Madison Ave, Anderson, IN 46011-3453 | |
| (317) 802-6302 | |
| Not Available |
| Full Name | Kevin Liebrum |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1515 N Madison Ave, Anderson, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649252586 | NPI | - | NPPES |
| 200387980 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 28154851 (Indiana) | Primary |
| Entity Name | Community Physicians Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619105244 PECOS PAC ID: 1759416662 Enrollment ID: O20100317000717 |
News Archive
Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature Immunology, may point a path to more effective vaccines.
"At least 100 relief workers in Afghanistan have been killed so far this year, far more than in any previous year, prompting a debate within humanitarian organizations about whether American military strategy is putting them and the Afghans they serve at unnecessary risk. ... Has American counterinsurgency strategy militarized the delivery of aid?" the New York Times writes looking at the different perspectives in this debate.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Liebrum, CRNA 6626 E 75th St, Suite 500, Indianapolis, IN 46250-2805 Ph: () - | Kevin Liebrum, CRNA 1515 N Madison Ave, Anderson, IN 46011-3453 Ph: (317) 802-6302 |
News Archive
Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature Immunology, may point a path to more effective vaccines.
"At least 100 relief workers in Afghanistan have been killed so far this year, far more than in any previous year, prompting a debate within humanitarian organizations about whether American military strategy is putting them and the Afghans they serve at unnecessary risk. ... Has American counterinsurgency strategy militarized the delivery of aid?" the New York Times writes looking at the different perspectives in this debate.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings.
› Verified 9 days ago
Krysta Ramey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2015 Jackson St, Anderson, IN 46016 Phone: 765-649-2500 | |
Brandon Johnston, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2015 Jackson St, Anderson, IN 46016 Phone: 765-649-2511 | |
Kathrine Annette Miller, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1515 N Madison Ave, Anderson, IN 46011 Phone: 765-298-2928 | |
Brittney Leigh Schiller, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2015 Jackson St, Anderson, IN 46016 Phone: 765-649-2511 | |
Jerri Goodman, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1515 N Madison Ave, Anderson, IN 46011 Phone: 317-802-6302 | |
Gregory A Yant, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1515 N Madison Ave, Anderson, IN 46011 Phone: 765-298-4242 | |
Amanda Christine Huddleston, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2015 Jackson St, Anderson, IN 46016 Phone: 765-649-2511 |